Publicaciones (138) Publicaciones en las que ha participado algún/a investigador/a

2023

  1. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

    Frontiers in Pharmacology

  2. Dietary Supplementation with a Cocoa–Carob Blend Modulates Gut Microbiota and Prevents Intestinal Oxidative Stress and Barrier Dysfunction in Zucker Diabetic Rats

    Antioxidants, Vol. 12, Núm. 8

  3. Glycolysis in pulmonary arterial hypertension and metabolic reprogramming

    Glycolysis: Tissue-Specific Metabolic Regulation in Physio-pathological Conditions (Elsevier), pp. 267-296

  4. Hydrogen sulfide regulates the redox state of soluble guanylate cyclase in CSE-/- mice corpus cavernosum microcirculation

    Pharmacological Research, Vol. 194

  5. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    Frontiers in Pharmacology, Vol. 14

  6. Novel Loss-of-Function KCNA5 Variants in Pulmonary Arterial Hypertension

    American Journal of Respiratory Cell and Molecular Biology, Vol. 69, Núm. 2, pp. 147-158

  7. Oxidized soluble guanylyl cyclase causes erectile dysfunction in alcoholic mice

    British Journal of Pharmacology, Vol. 180, Núm. 18, pp. 2361-2376

  8. Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart

    Journal of Physiology, Vol. 601, Núm. 17, pp. 3717-3737

  9. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities

    PLoS pathogens, Vol. 19, Núm. 1, pp. e1011063

  10. Sigma-1 receptor modulation fine-tunes KV1.5 channels and impacts pulmonary vascular function

    Pharmacological Research, Vol. 189

  11. Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension

    Frontiers in Pharmacology, Vol. 14

  12. Targeting IL-11 system as a treatment of pulmonary arterial hypertension

    Pharmacological research, Vol. 197, pp. 106985

  13. The novel KV7 channel activator URO-K10 exerts enhanced pulmonary vascular effects independent of the KCNE4 regulatory subunit

    Biomedicine and Pharmacotherapy, Vol. 164

  14. Topography of immune cell infiltration in different stages of coronary atherosclerosis revealed by multiplex immunohistochemistry

    IJC Heart and Vasculature, Vol. 44

  15. Vitamin D Receptor Deficiency Upregulates Pulmonary Artery Kv7 Channel Activity

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

  16. ¿Atrapados en la Facultad de Medicina?

    Conference proceedings CIVINEDU 2023: 7th International Virtual Conference on Educational Research and Innovation September 20-21, 2023